[Compound with bronchospasmolytical activity from the chemical class of beta-phenylethyl-aminoalkyl-xanthines (author's transl)].
1. 7-(3-[2-(3,5-Dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, D 1959, Bronchospasmin) was developed as a bronchospasmolytic agent from the structure class of the phenylethyl-aminoalkyl-xanthines. 2. The pharmacological effects characterize reproterol as a bronchospasmolytic with preferential impact on the adrenergic beta2-receptors. 3. In the therapeutic dose range, reproterol stands out because of its nearly non-existent cardiovascular or central nervous side effects. Effects of over and above pharmacodynamically effective doses as well as toxic ones may be reversed with beta1-receptor blockers.
D000318:Adrenergic beta-Agonists; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D001993:Bronchodilator Agents / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D004285:Dogs; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D009921:Metaproterenol / Q000494:pharmacology; D051379:Mice; D009130:Muscle, Smooth / Q000187:drug effects; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D010627:Phenethylamines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D014970:Xanthines / Q000494:pharmacology* / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D010627:Phenethylamines; D014970:Xanthines; D009921:Metaproterenol
Pharmakologische Untersuchungen der neuen Substanz Reproterol mit bronchospasmolytischer Wirkung aus der Substanzklasse der beta-Phenyläthyl-aminoalkyl-xanthine